Fintel on MSN19h
Needham Downgrades Biogen (BIIB)
Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.
BioPharma Dive3d
How a Biogen drug set the stage for a new biotech targeting ALS
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...
Fintel on MSN3d
Wolfe Research Initiates Coverage of Biogen (BIIB) with Peer Perform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Biogen (NasdaqGS:BIIB) with a Peer Perform ...
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, ...
FierceBiotech18d
Chutes & Ladders—Biogen boosts C-suite with BMS vet
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...
Nasdaq19d
Biogen Inc. Raises 2024 Financial Outlook Amid Product Launch Success
Biogen Inc. ( (BIIB)) has realeased its Q3 earnings. Here is a breakdown of the information Biogen Inc. presented to its investors. Biogen Inc. is a leading biotechnology company that specializes ...
ENDPOINTS NEWS19d
Hints of im­pa­tience grow with Bio­gen as it tries to find a bridge to growth
Bio­gen’s in­vestors are grow­ing rest­less. Wednes­day’s third-quar­ter earn­ings call checked most of the box­es for a suc­cess­ful re­port. The com­pa­ny raised its full-year ...
FiercePharma19d
Biogen boosts profit guidance despite modest quarter for Leqembi and multiple sclerosis downturn
Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. But to truly unlock the amyloid-busting antibody’s potential, the company will ...
Bloomberg L.P.19d
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth Quarterly Leqembi sales reached $67 million, beating estimates Cost cuts to drive high-teen percentage operating income boost ...
bnnbloomberg19d
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth
(Bloomberg) -- Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance ...
FierceBiotech19d
Biogen buys in to molecular glues with Neomorph deal worth up to $1.45B
Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...
The Boston Globe20d
Biogen raises forecast as Alzheimer’s drug Leqembi shows signs of growth
Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...